SGEN:NSD-Seagen Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 147.49

Change

+2.73 (+1.89)%

Market Cap

USD 26.25B

Volume

0.82M

Average Target Price

USD 183.21 (+24.22%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing SGEN

Symbol Name Weight Mer Price(Change) Market Cap
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+3.23 (+3.80%)

USD0.20B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.86 (-3.91%)

USD0.01B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.46 %

+2.99 (+1.97%)

USD10.74B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.58 %

+1.61 (+2.18%)

USD0.28B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

+1.67 (+2.94%)

USD0.16B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.15 (+2.27%)

USD0.34B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.11 (+2.26%)

USD0.34B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.16 (+2.28%)

USD0.03B
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.40 %

+0.22 (+2.14%)

USD2.13B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.12 (+2.12%)

USD0.35B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.79% 29% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.79% 29% F 14% F
Trailing 12 Months  
Capital Gain 6.09% 42% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.09% 42% F 17% F
Trailing 5 Years  
Capital Gain 273.58% 84% B 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 273.58% 84% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 40.69% 71% C- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.69% 71% C- 83% B
Risk Return Profile  
Volatility (Standard Deviation) 45.96% 68% D+ 37% F
Risk Adjusted Return 88.53% 98% A+ 91% A-
Market Capitalization 26.25B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 42.96 21% F 27% F
Price/Book Ratio 7.49 30% F 23% F
Price / Cash Flow Ratio 30.64 5% F 15% F
EV/EBITDA 35.78 21% F 28% F
Management Effectiveness  
Return on Equity 22.88% 96% A 92% A-
Return on Invested Capital 22.18% 93% A 93% A
Return on Assets 12.02% 97% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.02 53% F 38% F
Short Percent 5.59% 56% F 36% F
Beta 0.88 74% C 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.